Be active. Be free. Experience real-life
superior treatment with PADTM Technology based drugs.
MC2 Therapeutics is a privately held emerging pharmaceutical company committed to build leadership in new innovative topical therapies for chronic inflammatory conditions that helps patients minimize the burden of disease. Read more about MC2 Therapeutics.
Our PAD™ Technology is a new class of vehicle that enables development of new topical drugs with superior real-life performance. Read more about our platform.
Our current pipeline includes programs in major chronic topical diseases such as psoriasis, atopic dermatitis, pruritus and dry and sensitive skin and eyes. Read more about our pipeline.
MC2 Therapeutics appoints Christopher S. Billis as Chief Commercial Officer
Copenhagen, October 25th, 2018 – MC2 Therapeutics A/S, a clinical-stage dermatology and eye care company ...